65 related articles for article (PubMed ID: 27665021)
1. A Rare Case of S310F Somatic ERBB2 Mutation in a HER2-Nonamplified Breast Cancer.
Jasra S; Opyrchal M; Norton L; Mehta R
Clin Breast Cancer; 2017 Feb; 17(1):e37-e41. PubMed ID: 27665021
[No Abstract] [Full Text] [Related]
2. HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.
Ben-Baruch NE; Bose R; Kavuri SM; Ma CX; Ellis MJ
J Natl Compr Canc Netw; 2015 Sep; 13(9):1061-4. PubMed ID: 26358790
[TBL] [Abstract][Full Text] [Related]
3. Ductal carcinoma in-situ arising within benign phyllodes tumours.
Lui SA; Oh HB; Wang S; Chan CW
Ann R Coll Surg Engl; 2018 Apr; 100(4):e97-e102. PubMed ID: 29484937
[TBL] [Abstract][Full Text] [Related]
4. Rates of
Gottesdiener LS; O'Connor S; Busam KJ; Won H; Solit DB; Hyman DM; Shoushtari AN
Clin Cancer Res; 2018 Dec; 24(23):5815-5819. PubMed ID: 30093446
[TBL] [Abstract][Full Text] [Related]
5. Moving precision forward: extending next generation sequencing to operable disease in less common breast cancer subtypes.
Thomas A; Shatsky R; Kalinsky K
Ann Oncol; 2024 Jan; 35(1):7-9. PubMed ID: 37871698
[No Abstract] [Full Text] [Related]
6. Neratinib for the treatment of breast cancer.
Prové A; Dirix L
Expert Opin Pharmacother; 2016 Nov; 17(16):2243-2248. PubMed ID: 27690680
[TBL] [Abstract][Full Text] [Related]
7. RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
Fumagalli D; Venet D; Ignatiadis M; Azim HA; Maetens M; Rothé F; Salgado R; Bradbury I; Pusztai L; Harbeck N; Gomez H; Chang TW; Coccia-Portugal MA; Di Cosimo S; de Azambuja E; de la Peña L; Nuciforo P; Brase JC; Huober J; Baselga J; Piccart M; Loi S; Sotiriou C
JAMA Oncol; 2017 Feb; 3(2):227-234. PubMed ID: 27684533
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.
Chen J; Kinoshita T; Sukbuntherng J; Chang BY; Elias L
Mol Cancer Ther; 2016 Dec; 15(12):2835-2844. PubMed ID: 27678331
[TBL] [Abstract][Full Text] [Related]
9. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
[TBL] [Abstract][Full Text] [Related]
10. Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.
Zuo WJ; Jiang YZ; Wang YJ; Xu XE; Hu X; Liu GY; Wu J; Di GH; Yu KD; Shao ZM
Clin Cancer Res; 2016 Oct; 22(19):4859-4869. PubMed ID: 27697991
[TBL] [Abstract][Full Text] [Related]
11. Herceptin-functionalized pure paclitaxel nanocrystals for enhanced delivery to HER2-postive breast cancer cells.
Noh JK; Naeem M; Cao J; Lee EH; Kim MS; Jung Y; Yoo JW
Int J Pharm; 2016 Nov; 513(1-2):543-553. PubMed ID: 27686050
[TBL] [Abstract][Full Text] [Related]
12. The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer.
Soria F; Moschini M; Haitel A; Wirth GJ; Gust KM; Briganti A; Rouprêt M; Klatte T; Hassler MR; Karakiewicz PI; Shariat SF
Urol Oncol; 2016 Dec; 34(12):533.e1-533.e10. PubMed ID: 27665356
[TBL] [Abstract][Full Text] [Related]
13. High-Throughput Functional Evaluation of Variants of Unknown Significance in
Nagano M; Kohsaka S; Ueno T; Kojima S; Saka K; Iwase H; Kawazu M; Mano H
Clin Cancer Res; 2018 Oct; 24(20):5112-5122. PubMed ID: 29967253
[No Abstract] [Full Text] [Related]
14. Systematic Functional Annotation of Somatic Mutations in Cancer.
Ng PK; Li J; Jeong KJ; Shao S; Chen H; Tsang YH; Sengupta S; Wang Z; Bhavana VH; Tran R; Soewito S; Minussi DC; Moreno D; Kong K; Dogruluk T; Lu H; Gao J; Tokheim C; Zhou DC; Johnson AM; Zeng J; Ip CKM; Ju Z; Wester M; Yu S; Li Y; Vellano CP; Schultz N; Karchin R; Ding L; Lu Y; Cheung LWT; Chen K; Shaw KR; Meric-Bernstam F; Scott KL; Yi S; Sahni N; Liang H; Mills GB
Cancer Cell; 2018 Mar; 33(3):450-462.e10. PubMed ID: 29533785
[TBL] [Abstract][Full Text] [Related]
15. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Robichaux JP; Elamin YY; Vijayan RSK; Nilsson MB; Hu L; He J; Zhang F; Pisegna M; Poteete A; Sun H; Li S; Chen T; Han H; Negrao MV; Ahnert JR; Diao L; Wang J; Le X; Meric-Bernstam F; Routbort M; Roeck B; Yang Z; Raymond VM; Lanman RB; Frampton GM; Miller VA; Schrock AB; Albacker LA; Wong KK; Cross JB; Heymach JV
Cancer Cell; 2019 Oct; 36(4):444-457.e7. PubMed ID: 31588020
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Potential of Afatinib for Cancers with
Yamamoto H; Toyooka S; Ninomiya T; Matsumoto S; Kanai M; Tomida S; Kiura K; Muto M; Suzawa K; Desmeules P; Kris MG; Li BT; Ladanyi M
Oncologist; 2018 Feb; 23(2):150-154. PubMed ID: 29146616
[TBL] [Abstract][Full Text] [Related]
17. A method of high-throughput functional evaluation of
Kohsaka S; Nagano M; Ueno T; Suehara Y; Hayashi T; Shimada N; Takahashi K; Suzuki K; Takamochi K; Takahashi F; Mano H
Sci Transl Med; 2017 Nov; 9(416):. PubMed ID: 29141884
[TBL] [Abstract][Full Text] [Related]
18. An application of ERBB2 receptor inhibitors in a rare case of S310F somatic ERBB2 mutation of primary signet-ring cell adenocarcinoma of vagina: A case report and review literature of S310F somatic ERBB2 mutation in breast and gynecologic cancers.
Hou JY; Wright JD; Achariyapota V
Gynecol Oncol Rep; 2020 May; 32():100577. PubMed ID: 32405522
[TBL] [Abstract][Full Text] [Related]
19. The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab.
Shin JW; Kim S; Ha S; Choi B; Kim S; Im SA; Yoon TY; Chung J
Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31635022
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
